Cover Image
市場調查報告書

第一三共:產品平台分析

Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224550
出版日期 內容資訊 英文 196 Pages
訂單完成後即時交付
價格
Back to Top
第一三共:產品平台分析 Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016
出版日期: 2016年10月12日 內容資訊: 英文 196 Pages
簡介

第一三共是進行製藥公司之研究、發展、製造與行銷的特殊公司,提供廣泛的處方藥、店頭(OTC)藥和醫藥部外品。此外他們將營業部門分為第一三共集團與Ranbaxy集團,透過日本及global group公司直接將產品投入市場,利用醫藥資訊負責人的大規模網路,將產品銷售到全球50個以上的國家,在南北美洲、歐洲及亞太地區全區發展業務。

本報告提供第一三共的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

第一三共的基本資料

  • 第一三共概要
  • 主要資訊
  • 企業資料

第一三共:R&D概要

  • 主要的治療範圍

第一三共:開發平台的評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
  • 轉出授權產品

第一三共:開發中產品概況

  • 最後階段的開發中產品
  • 臨床實驗階段的開發中產品
  • 初期階段的開發中產品

第一三共:藥物簡介

  • edoxaban tosylate
  • levofloxacin
  • methylene blue
  • CL-108
  • denosumab
  • etanercept biosimilar
  • hydromorphone hydrochloride
  • KIB-PCI
  • mirogabalin
  • nimotuzumab
  • patritumab
  • prasugrel hydrochloride
  • tivantinib
  • VN-0103
  • VN-100
  • CS-3150
  • DS-8500
  • efatutazone
  • exatecan mesylate
  • laninamivir
  • tigatuzumab
  • DS-1040
  • DS-1093
  • DS-1150b
  • DS-1971
  • DS-3032
  • DS-3078
  • DS-3801
  • DS-5573a
  • DS-6051
  • DS-7423
  • DS-8273
  • DS-8895
  • Small Molecule to Inhibit Ubiquitin Ligase for Cancer
  • U3-1565
  • Antibody Drug Conjugate for Solid Tumors
  • CS-1050
  • DC-159a
  • DF-461
  • DS-1558
  • DS-8108b
  • Monoclonal Antibodies for Undisclosed Indication
  • PN1-Ab
  • Protein for Undiscosed Indication
  • Recombinant Proteins 2 for Undisclosed Indication
  • RS-1269
  • Small Molecule for Respiratory Tract Infections
  • Small Molecule to Agonize PPAR Alpha and PPAR Gamma for Metabolic Disorders
  • Small Molecule to Agonize PPAR Gamma Receptor for Type 2 Diabetes
  • Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis
  • Small Molecule to Inhibit PDE4 for COPD
  • Small Molecule to Inhibit PDE4B for Lung Inflammation
  • Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis
  • Small Molecule to Inhibit VLA-4 for Asthma
  • Small Molecules to Inhibit FATP1 for Undisclosed Indication
  • Small Molecules to Inhibit p53-MDM2 Interaction for Cancer
  • Small Molecules to Inhibit Renin for Hypertension
  • SQ-641
  • U3-1784
  • Antisense Oligonucleotide for Duchenne Muscular Dystrophy
  • Beta-Cell Regeneration Program
  • Drugs for Cancer
  • Drugs for Oncology, Cardiovascular and Metabolic Diseases
  • DS-5272
  • Pedopeptins to Inhibit LPS for Bacterial Infection
  • Small Molecule for Cardiovascular-Metabolic Diseases
  • Small Molecule for Tuberculosis
  • Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections
  • Small Molecules for Malaria
  • Small Molecules for Multiple Neurodegenerative Diseases
  • Small Molecules for Osteopenia and Osteoporosis
  • Small Molecules to Agonize BRS-3 for Undisclosed Indication
  • Sphaerimicin A
  • U-31201
  • U-31910
  • U-31987

第一三共:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

第一三共:最近的開發平台趨勢

第一三共:暫停中的計劃

第一三共:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • AJD-101
    • AKU-517
    • pactimibe
    • CS-758..
    • CS-8080
    • Sun-E7001
    • AJD-101
    • ASB-17061
    • carperitide
    • CS-003
    • CS-0777
    • CS-1036
    • CS-4771
    • CS-8080
    • DB-772d
    • DC-159a
    • DS-1442
    • DS-2248
    • DS-6930
    • DS-7250
    • DS-7309
    • DS-8587
    • DX-619
    • DX-9065a
    • DZ-697b
    • efatutazone
    • nefiracetam
    • nimotuzumab
    • prasugrel hydrochloride
    • rivoglitazone
    • tigatuzumab
    • tivantinib
    • tomopenem

第一三共:企業發表

第一三共:總公司和子公司的所在地

第一三共:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08153CDB

Summary

Global Markets Direct's, 'Daiichi Sankyo Company, Limited - Product Pipeline Review - 2016', provides an overview of the Daiichi Sankyo Company, Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Daiichi Sankyo Company, Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Daiichi Sankyo Company, Limited
  • The report provides overview of Daiichi Sankyo Company, Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Daiichi Sankyo Company, Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Daiichi Sankyo Company, Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Daiichi Sankyo Company, Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Daiichi Sankyo Company, Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Daiichi Sankyo Company, Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Daiichi Sankyo Company, Limited Snapshot
    • Daiichi Sankyo Company, Limited Overview
    • Key Facts
  • Daiichi Sankyo Company, Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Daiichi Sankyo Company, Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Daiichi Sankyo Company, Limited - Pipeline Products Glance
  • Daiichi Sankyo Company, Limited - Late Stage Pipeline Products
  • Daiichi Sankyo Company, Limited - Clinical Stage Pipeline Products
  • Daiichi Sankyo Company, Limited - Early Stage Pipeline Products
  • Daiichi Sankyo Company, Limited - Unknown Stage Pipeline Products
  • Daiichi Sankyo Company, Limited - Drug Profiles
    • A-503451A - Drug Profile
    • CS-1050 - Drug Profile
    • DC-159a - Drug Profile
    • denosumab - Drug Profile
    • DF-461 - Drug Profile
    • Drug to Inhibit IDH1 for Acute Myelocytic Leukemia and Glioma - Drug Profile
    • Drugs for Oncology, Cardiovascular and Metabolic Diseases - Drug Profile
    • DS-1040 - Drug Profile
    • DS-1093 - Drug Profile
    • DS-1123 - Drug Profile
    • DS-1501 - Drug Profile
    • DS-1558 - Drug Profile
    • DS-1971 - Drug Profile
    • DS-2330 - Drug Profile
    • DS-2969 - Drug Profile
    • DS-3032 - Drug Profile
    • DS-3201 - Drug Profile
    • DS-5141 - Drug Profile
    • DS-5272 - Drug Profile
    • DS-5573a - Drug Profile
    • DS-6051 - Drug Profile
    • DS-7080 - Drug Profile
    • DS-8108b - Drug Profile
    • DS-8201 - Drug Profile
    • DS-8273 - Drug Profile
    • DS-8500 - Drug Profile
    • DS-8895 - Drug Profile
    • DS-9001 - Drug Profile
    • DS-9231 - Drug Profile
    • edoxaban tosylate - Drug Profile
    • efatutazone - Drug Profile
    • esaxerenone - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etirinotecan pegol - Drug Profile
    • hydromorphone hydrochloride - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
    • laninamivir - Drug Profile
    • mirogabalin besylate - Drug Profile
    • Monoclonal Antibodies for Undisclosed Indication - Drug Profile
    • Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer - Drug Profile
    • nimotuzumab - Drug Profile
    • patritumab - Drug Profile
    • Pedopeptins to Inhibit LPS for Bacterial Infection - Drug Profile
    • PLX-51107 - Drug Profile
    • PLX-73086 - Drug Profile
    • PLX-7486 - Drug Profile
    • PLX-8394 - Drug Profile
    • PLX-9486 - Drug Profile
    • prasugrel hydrochloride - Drug Profile
    • Protein for Undisclosed Indication - Drug Profile
    • quizartinib dihydrochloride - Drug Profile
    • R-xxx - Drug Profile
    • Small Molecule for Cardiovascular-Metabolic Diseases - Drug Profile
    • Small Molecule for Respiratory Tract Infections - Drug Profile
    • Small Molecule for Tuberculosis - Drug Profile
    • Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile
    • Small Molecule to Agonize PPAR Alpha and PPAR Gamma for Metabolic Disorders - Drug Profile
    • Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
    • Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile
    • Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile
    • Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis - Drug Profile
    • Small Molecule to Inhibit PDE4 for COPD - Drug Profile
    • Small Molecule to Inhibit PDE4B for Lung Inflammation - Drug Profile
    • Small Molecule to Inhibit Renin for Hypertension - Drug Profile
    • Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile
    • Small Molecules for Malaria - Drug Profile
    • Small Molecules for Multiple Neurodegenerative Diseases - Drug Profile
    • Small Molecules for Osteopenia and Osteoporosis - Drug Profile
    • Small Molecules to Agonize BRS-3 for Obesity - Drug Profile
    • Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile
    • Small Molecules to Inhibit FATP1 for Undisclosed Indication - Drug Profile
    • Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile
    • Small Molecules to Inhibit Nav1.7 for Pain - Drug Profile
    • Small Molecules to Inhibit p53-MDM2 Interaction for Cancer - Drug Profile
    • Sphaerimicin A - Drug Profile
    • SQ-641 - Drug Profile
    • Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile
    • tivantinib - Drug Profile
    • U-31402 - Drug Profile
    • U-3771 - Drug Profile
    • U-3808 - Drug Profile
    • U3-1784 - Drug Profile
    • VN-0102 - Drug Profile
    • VN-0103 - Drug Profile
    • VN-0104 - Drug Profile
    • VN-0105 - Drug Profile
    • VN-100 - Drug Profile
  • Daiichi Sankyo Company, Limited - Pipeline Analysis
    • Daiichi Sankyo Company, Limited - Pipeline Products by Target
    • Daiichi Sankyo Company, Limited - Pipeline Products by Route of Administration
    • Daiichi Sankyo Company, Limited - Pipeline Products by Molecule Type
    • Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action
  • Daiichi Sankyo Company, Limited - Dormant Projects
  • Daiichi Sankyo Company, Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Daiichi Sankyo Company, Limited - Company Statement
  • Daiichi Sankyo Company, Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Daiichi Sankyo Company, Limited, Key Facts
  • Daiichi Sankyo Company, Limited - Pipeline by Indication, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016
  • Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016
  • Daiichi Sankyo Company, Limited - Combination Treatment Modalities in Pipeline, 2016
  • Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016
  • Daiichi Sankyo Company, Limited - Partnered Products/ Combination Treatment Modalities, 2016
  • Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016
  • Daiichi Sankyo Company, Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Daiichi Sankyo Company, Limited - Pre-Registration, 2016
  • Daiichi Sankyo Company, Limited - Phase III, 2016
  • Daiichi Sankyo Company, Limited - Phase II, 2016
  • Daiichi Sankyo Company, Limited - Phase I, 2016
  • Daiichi Sankyo Company, Limited - Preclinical, 2016
  • Daiichi Sankyo Company, Limited - Discovery, 2016
  • Daiichi Sankyo Company, Limited - Unknown, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Target, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Molecule Type, 2016
  • Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action, 2016
  • Daiichi Sankyo Company, Limited - Dormant Developmental Projects,2016
  • Daiichi Sankyo Company, Limited - Discontinued Pipeline Products, 2016
  • Daiichi Sankyo Company, Limited, Subsidiaries

List of Figures

  • Daiichi Sankyo Company, Limited - Pipeline by Top 10 Indication, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2016
  • Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2016
  • Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2016
  • Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Top 10 Target, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2016
  • Daiichi Sankyo Company, Limited - Pipeline by Top 10 Molecule Type, 2016
  • Daiichi Sankyo Company, Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top